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Background: Older women with breast cancer have poorer relative survival outcomes, but whether achieving earlier stage at
diagnosis would translate to substantial reductions in mortality is uncertain.
Methods: We analysed data on East of England women with breast cancer (2006–2010) aged 70þ years. We estimated
survival for different stage-deprivation-age group strata using both the observed and a hypothetical stage distribution
(assuming that all women aged 75þ years acquired the stage distribution of those aged 70–74 years). We subsequently
estimated deaths that could be postponed beyond 5 years from diagnosis if women aged 75þ years had the hypothetical
stage distribution. We projected findings to the English population using appropriate age and socioeconomic group
weights.
Results: For a typically sized annual cohort in the East of England, 27 deaths in women with breast cancer aged 75þ years can be
postponed within 5 years from diagnosis if their stage distribution matched that of the women aged 70–74 years (4.8% of all 566
deaths within 5 years post diagnosis in this population). Under assumptions, we estimate that the respective number for England
would be 280 deaths (5.0% of all deaths within 5 years post diagnosis in this population).
Conclusions: The findings support ongoing development of targeted campaigns aimed at encouraging prompt presentation in
older women.
Across Europe, older patients have benefited least from the
substantial improvements in cancer survival in recent decades
(Quaglia et al, 2009). Age gaps in cancer survival have been
greatest in the UK and Ireland (De Angelis et al, 2014). Although
some of these age inequalities may reflect sub-optimal manage-
ment (Lavelle et al, 2007), another part may reflect that older
patients are diagnosed at more advanced disease stage. For
example, in England, older persons are at a greater risk of
advanced stage at diagnosis of melanoma, endometrial and breast
cancers (Lyratzopoulos et al, 2013a).
In England, about 6000 deaths in women aged 70 years or over
are attributed to breast cancer each year (Office for National
Statistics, 2013), and around a third of all new diagnoses of breast
cancer occur in this age group (Cancer Research UK (CRUK)
Website, 2014). In theory, decreasing the proportion of
older women who are diagnosed with advanced-stage breast
cancer should help prolong survival. Establishing the size of
anticipated reduction in mortality using empirical evidence from
population-based cohorts would be useful. Against this back-
ground, we have set out to examine the potential for preventing
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deaths within 5 years from diagnosis of breast cancer in older
women that could result from eliminating age inequalities in
stage at diagnosis.
MATERIALS AND METHODS
Data. We analysed time from diagnosis to death for East of
England women aged 70 years or over with a new diagnosis of
breast cancer (International Classification of Diseases–10 site code
C50) during 2006–2010, with follow-up on mortality until 15
March 2012. As described previously (Rutherford et al, 2013b), the
data were extracted from the (former) Eastern Cancer Registration
and Information Centre (ECRIC), a cancer registry covering a
population of B5.7 million across the East of England region.
Stage at diagnosis was assigned by medical practitioners with
specialist expertise, based on clinical, imaging and pathological
information according to the TNM classification (Sobin and
Fleming, 1997). Socioeconomic status groups (one least deprived,
five most deprived) were defined ecologically, using national
quintiles of the income domain of the Index of Multiple
Deprivation 2010 score of the Lower Super Output Area of
patients’ residence at diagnosis (Department for Communities and
Local Government, 2011). We categorised age into four groups:
70–74, 75–79, 80–84 and 85þ years. Deprivation and age
information were available for all patients. The data on age group
and deprivation are tabulated in Table 1.
Analysis. We used a similar approach to Rutherford et al (2013b)
but with matching of stage distributions across age rather than
deprivation groups. Full details of the method are described in the
methods section and appendix of the previously published paper
(Rutherford et al, 2013b). Briefly, we fitted a flexible parametric
excess mortality model (Nelson et al, 2007; Royston and Lambert,
2011) to estimate the effect of age, stage and deprivation status on
excess mortality. We then calculated the proportion of women
diagnosed at each stage for all deprivation-age group strata to
obtain the relevant weights for the stage standardisation. Using the
model estimates and these weights, we calculated stage-standar-
dised survival for each age and deprivation group using two
different stage distributions; one based on the observed stage
distribution in each category and the second based on the stage
distribution (in the respective deprivation group) for women aged
70–74 years. We calculated the difference between these two
standardised survival estimates while accounting for other cause
mortality, and we report the number of deaths postponed beyond
given points during the follow-up period (i.e., beyond 5 years) by
‘equalising’ the stage distribution of each age group to match that
of women in the 70- to 74-year group. We used a complete case
analysis approach and deprivation quintile-specific life-tables for
all survival estimates (Cancer Research UK Cancer Survival Group,
2006). Confidence intervals for the number of postponable deaths
were calculated using the delta method using a similar approach to
that described by Seppa et al (2012).
We also approximated the number of deaths that could be
postponed in the whole of England rather than just the East of
England region by appropriately weighting the estimates
(Rutherford et al, 2013b) to match the age and socioeconomic
group distribution for those aged 70þ years in England as a
whole. This involved re-weighting the estimates to account for
sample size and compositional differences (e.g., regarding depriva-
tion group) between the populations of East of England and
England.
Supplementary analysis. We examined the potential for con-
founding by tumour type by exploring associations between age
group and morphology, and morphology and stage. Using
International Classification of Diseases-Oncology morphology
codes, four tumour groups (infiltrating ductal carcinoma, infiltrat-
ing lobular carcinoma, mixed infiltrating ductal and lobular
carcinoma, and other unspecified types) were used for this analysis.
RESULTS
There were 6478 women aged X70 years with complete
information on stage at diagnosis included in subsequent analysis
(88% of an initial total of 7331 women). The proportion of women
with missing stage information was 6.2%, 7.6%, 12.8% and 20% for
age groups 70–74 years, 75–79 years, 80–84 years and 85þ years,
respectively. As previously reported (Lyratzopoulos et al, 2013a),
among women with known stage, the proportion diagnosed in
earlier stage progressively decreases with age over 70 years. For
example, the proportion of women diagnosed at stage I is 39% for
women aged 70–74 years, whereas it is only 23% for the 85þ age
group; these age gradients are similar across deprivation groups
(Table 1).
Stage-specific survival is markedly different for stage I compared
with stages III or IV, across age groups (Figure 1). Therefore, if the
distribution of stage at diagnosis for the older women matched that
of those aged 70–74 years, there should be measurable improve-
ments in survival, translating to a number of all-cause deaths that
could be postponed.
Figure 1 shows the stage-specific survival for women aged 70–
74, 75–79, 80–84 and 85þ years. Relative survival for women
diagnosed at stage I is nearly 100% during the entire follow-up
period (i.e., up to 5 years from diagnosis) and for all age groups.
Table 1. Stage distributions across age and deprivation
groups
Stage I Stage II Stage III Stage IV Total
Most affluent
70–74 182 (41.27) 200 (45.4) 40 (9.1) 19 (4.3) 441 (100)
75–79 173 (37.0) 220 (47.0) 55 (11.8) 20 (4.3) 468 (100)
80–84 103 (32.2) 155 (48.4) 38 (11.9) 24 (7.5) 320 (100)
85þ 70 (22.7) 168 (54.6) 47 (15.3) 23 (7.5) 308 (100)
Deprivation group 2
70–74 183 (39.1) 220 (47.0) 55 (11.8) 20 (4.3) 468 (100)
75–79 145 (30.8) 133 (44.9) 31 (10.5) 21 (7.1) 471 (100)
80–84 93 (26.7) 163 (46.8) 50 (14.4) 42 (12.1) 348 (100)
85þ 91 (24.1) 185 (48.9) 67 (17.7) 35 (9.3) 378 (100)
Deprivation group 3
70–74 174 (39.0) 193 (43.3) 38 (8.5) 41 (9.2) 446 (100)
75–79 158 (35.5) 197 (44.3) 49 (11.0) 41 (9.2) 445 (100)
80–84 118 (29.4) 190 (47.3) 47 (11.7) 47 (11.7) 402 (100)
85þ 94 (23.6) 199 (50.0) 68 (17.1) 37 (9.3) 398 (100)
Deprivation group 4
70–74 111 (37.5) 133 (44.9) 31 (10.5) 21 (7.1) 296 (100)
75–79 91 (27.7) 156 (47.6) 36 (11.0) 45 (13.7) 328 (100)
80–84 69 (24.0) 149 (51.9) 41 (14.3) 28 (9.8) 287 (100)
85þ 71 (22.9) 158 (51.0) 63 (20.3) 18 (5.8) 310 (100)
Most deprived
70–74 41 (40.6) 43 (42.6) 9 (8.9) 8 (7.9) 101 (100)
75–79 32 (33.3) 45 (46.9) 12 (12.5) 7 (7.29) 96 (100)
80–84 19 (25.3) 37 (49.3) 16 (21.33) 3 (4.0) 75 (100)
85þ 19 (20.7) 39 (42.4) 26 (28.3) 8 (8.7) 92 (100)
Total (over deprivation groups)
70–74 691 (39.4) 769 (43.9) 172 (9.8) 120 (6.9) 1752 (100)
75–79 599 (33.1) 856 (47.4) 203 (11.2) 150 (8.3) 1808 (100)
80–84 402 (28.1) 694 (48.5) 192 (13.4) 144 (10.1) 1432 (100)
85þ 345 (23.22) 749 (50.4) 271 (18.2) 121 (8.1) 1486 (100)
Total (overall)
70þ 2037 (31.4) 3068 (47.4) 838 (12.9) 535 (8.26) 6478 (100)
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In other words, women diagnosed at stage I experience almost no
excess mortality compared with those in the general population
without breast cancer. Stage-specific survival is fairly similar across
all age groups (Figure 1). The relative survival for patients
diagnosed at stage III or IV is quite poor across all age groups (for
example, the 5-year relative survival for women diagnosed at stage
III is B40%, Figure 1), indicating that these women have a
considerable excess mortality owing to breast cancer.
Figure 2 shows the number of deaths that can be postponed
beyond certain points during the follow-up period by achieving
earlier stage distribution in the three older age groups (i.e., by
matching their stage distribution to that of women aged 70–74 years
within the same deprivation groups). Figure 2A shows the relevant
estimates for the East of England for (a typical annual cohort of 1296
cases) showing that 27 deaths (point estimate of 27.2 with 95% CI
25.2 to 29.2) can be postponed to a time point beyond 5 years from
diagnosis. This would represent 4.8% of all 566 deaths calculated to
occur within 5 years from diagnosis in women with breast cancer
aged470 years in East of England. Figure 2B shows the re-weighted
estimates for England using 2009 incidence figures for those aged
X70 years—about 280 deaths postponed beyond 5 years among
older women, or 5.0% of all deaths in the respective population.
DISCUSSION
There is potential for reducing excess mortality from breast cancer
by eliminating age inequalities in stage at diagnosis in women aged
70 years or over. This reduction in excess mortality will have a
direct impact on all-cause survival estimates, and we estimate that
around 280 deaths would be postponed beyond 5 years for a typical
annual cohort size of older (70þ ) women with breast cancer in
England.
Strengths of our study include the use of a large population-
based sample with good quality and completeness of information
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Figure 1. Stage-specific survival across the age groups 70–74, 75–79, 80–84 and 85þ years.
0
2
4
6
8
10
12
N
um
be
r o
f p
os
tp
on
ab
le
 d
ea
th
s
0 1 2 3 4 5
Follow−up (years)
75−79
80−84
85+
0
50
100
150
N
um
be
r o
f p
os
tp
on
ab
le
 d
ea
th
s
0 1 2 3 4 5
Follow−up (years)
75−79
80−84
85+
Figure 2. Number of avoidable deaths within 5 years from diagnosis of
cancer. (A) East of England. (B) England. Note the different y-axis scales
in the two sub-figures. Total values across all age groups at 5 years:
27.17 deaths in East of England, 278.59 deaths for England.
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on stage at diagnosis, and the use of a flexible parametric model,
allowing for the smooth estimation of excess mortality throughout
the follow-up period while appropriately accounting for the effects
of deprivation and age (Rutherford et al, 2013a). The methodology
that we have used in this paper can help support monitoring of the
impact of population-based early awareness and detection inter-
ventions (Be Clear On Cancer—Breast Cancer in Over 70s
Campaign, 2014).
We restricted our study population to a historical cohort of East
of England women (2006–10) with both high level of completeness
of information on stage at diagnosis and an adequate follow-up
period. As recording of stage information becomes increasingly
complete and consistent across England, future work should aim to
encompass more recent cohorts of patients using nationwide data.
Limiting to regional data means that we have small numbers for
some of the cells in Table 1, particularly for the most-deprived
patients and late-stage disease. Extrapolating the regional estimates
to England as a whole makes the assumption that patients with
breast cancer in England do not differ from those in the East of
England in terms of expected survival, the effect of the covariates
on relative survival and the distribution of stage at diagnosis.
Overall, these assumptions appear to be fairly reasonable, particularly
given only modest variation in short-term relative survival for breast
cancer patients between the English regions (Rachet et al, 2009).
To further aid interpretation and to contextualise the findings,
we would like to draw attention to the fact that all deaths estimated
in our paper are actually postponed (an alternative term used for
this measure is avoidable deaths)—the entire cohort will eventually
diminish to 0 if follow-up is extended long enough. For women
aged 85þ years in particular, the estimated number of postponed
deaths begins to decrease within 5 years from diagnosis (Figure 2),
as other cause mortality is particularly high in that age group.
Further, the findings need to be interpreted in the context of
previous work examining potential survival gains by eliminating
socioeconomic inequalities in stage at diagnosis of breast cancer
among women of any age (Rutherford et al, 2013b). In contrast,
the present study solely focuses on age inequalities in stage at
diagnosis among older women. Combined elimination of inequal-
ities in stage at diagnosis both by socioeconomic and older age
groups would be associated with a greater number of deaths that
can be postponed beyond 5 years from diagnosis in the population.
Three issues deserve further discussion. First, our method does
not make any adjustment for differences in tumour type across age
groups. We have shown in supplementary analyses that differences
in morphology by age are unlikely to be large (Supplementary
Online Material Tables 1 and 2). Although there are some
differences in the stage distribution across morphology groups
(Supplementary Online Material Table 3), tumour type does not
have a large impact on survival in addition to stage. Although
breast cancer is known to be a heterogeneous disease, most of the
tumour type differences relate to pre-menopausal compared with post-
menopausal women (Anderson et al, 2014). In contrast, our study
population only included (post-menopausal) women agedX70 years.
Second, we excluded women below the age of 70 years owing to
the impact of screening. Screen detection has an impact on stage at
diagnosis (the great majority of screen-detected cases will be
diagnosed at stages I or II) and could introduce differential lead
time bias in the survival estimates. Evidence does not, at least
currently, support the offer of screening in older women
(Independent UK Panel on Breast Cancer Screening, 2012; de
Glas et al, 2014), although this is the subject of ongoing research
(CRUK Website—A study to evaluate an age extension to the NHS
Breast Screening Programme, 2014). However, our method could
be sensitive to the use of screening in our sample. The proportion
of women in our study population who were screening-detected
differs by age (26%, 12%, 3% and 1% for women aged 70–74, 75–
79, 80–84 and 85þ years, respectively). It is likely that these
differences largely reflect age variation in use (as opposed to
effectiveness) of screening. Owing to the level of screening use in
women aged 70–74, our global estimate of avoidable all-cause
deaths in women aged 70 years or older may be upwardly inflated.
Nevertheless, further potential gains in the number of postponable
deaths in women older than 70 could be made by achieving a
(more favourable) stage distribution that would be seen for patients
aged 65–69 years. However, this comparison is made difficult by
the high use of screening in this group (over half of all women aged
65–69 are detected by screening).
Finally, older age is associated with both a greater risk of
advanced stage at diagnosis and missing stage information.
Therefore, and as our findings are based on a complete case
analysis, the true potential for avoidable deaths may have been
under-estimated. In addition, the higher concentration of
(excluded) cases with missing stage in older age groups leads to
differential reduction of the sample size, again resulting in
underestimation of the true potential for reducing deaths in older
women. On the other hand, women with missing stage disease also
have fairly poor survival, and therefore our stage-specific survival
estimates may be upwardly biased to a small degree.
In their largest part, age differentials in stage at diagnosis of
breast cancer in women aged X70 years are likely to reflect age
differences in promptness of presentation (i.e., age differences in
the patient interval) as opposed to differences in diagnostic
intervals after presentation. This is because after seeking medical
help with relevant symptoms, the great majority of English women
subsequently diagnosed with breast cancer are referred very
promptly independently of their age (median primary care
interval¼ 0 days, interquartile range: 0–1; Lyratzopoulos et al,
2013b), with concordant evidence from Scotland (Baughan et al,
2009). Further, older age confers no disadvantage in speed of
specialist referral (Lyratzopoulos et al, 2012).
We did not have information on co-morbidity in our study,
which increases with age. However, as we estimate survival within
age groups, this will lessen the impact of differential co-morbidity
by age. Further, evidence from the US indicates that greater levels
of co-morbidity may be associated with earlier stage at diagnosis of
breast and colorectal cancer, possibly because of greater opportu-
nities to detect cancer early in more co-morbid patients through
more frequent care appointments (Keating et al, 2005, Zafar et al,
2008). Therefore, the fact that older women could be expected to
have greater levels of co-morbidity could facilitate rather than
impede earlier stage at diagnosis.
Our findings therefore provide support both for further research
to establish the causes of age inequalities in stage at diagnosis of
breast cancer and ongoing public health campaigns aimed to
encourage prompt presentation in older women (Be Clear On
Cancer—Breast Cancer in Over 70s Campaign, 2014). Such
campaigns can, for example, aim to increase awareness of cancer
signs and symptoms (a conceptual surrogate of the patient interval;
Lyratzopoulos, 2014), which is lower among older patients (Robb
et al, 2009; Forbes et al, 2011), or they can aim to increase the public
understanding of the age-dependent nature of breast cancer risk,
which is low in the general English population (Forbes et al, 2013).
Subject to appropriate development, validation and evaluation,
campaigns that target women aged 70þ years should be
encouraged, as they can lead to substantial reductions in avoidable
mortality through earlier stage diagnosis of breast cancer in these
women.
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